Biagio Ricciuti, Giuseppe Lamberti, Sreekar R Puchala, Navin R Mahadevan, Jia-Ren Lin, Joao V Alessi, Alexander Chowdhury, Yvonne Y Li, Xinan Wang, Liam Spurr, Federica Pecci, Alessandro Di Federico, Deepti Venkatraman, Adriana P Barrichello, Malini Gandhi, Victor R Vaz, Andy J Pangilinan, Danielle Haradon, Elinton Lee, Hersh Gupta, Kathleen L Pfaff, Emma L Welsh, Mizuki Nishino, Andrew D Cherniack, Bruce E Johnson, Jason L Weirather, Ian D Dryg, Scott J Rodig, Lynette M Sholl, Peter Sorger, Sandro Santagata, Renato Umeton, Mark M Awad
PURPOSE: Although immune checkpoint inhibitors (ICI) have extended survival in patients with non-small-cell lung cancer (NSCLC), acquired resistance (AR) to ICI frequently develops after an initial benefit. However, the mechanisms of AR to ICI in NSCLC are largely unknown. METHODS: Comprehensive tumor genomic profiling, machine learning-based assessment of tumor-infiltrating lymphocytes, multiplexed immunofluorescence, and/or HLA-I immunohistochemistry (IHC) were performed on matched pre- and post-ICI tumor biopsies from patients with NSCLC treated with ICI at the Dana-Farber Cancer Institute who developed AR to ICI...
January 11, 2024: Journal of Clinical Oncology